The marketplace for weight problems and diabetes therapies stays scorching sizzling, funneling billions in gross sales to Eli Lilly and fueling a bidding warfare over one other drugmaker.
Lilly mentioned Thursday that its top-selling medication, Mounjaro and Zepbound, introduced in additional than $10 billion mixed throughout the not too long ago accomplished third quarter. That made up over half of the drugmaker’s $17.6 billion in whole gross sales.
Individually, Danish drugmaker Novo Nordisk introduced plans to purchase Metsera Inc. in a deal that could possibly be price as much as $9 billion.
That got here greater than a month after U.S. drugmaker Pfizer Inc. made a nearly $5 billion bid for Metsera, which has no medication in the marketplace however is growing a number of potential oral and injectable therapies.
Well-liked therapies labeled GLP-1 receptor agonists are fueling the hovering gross sales and deal curiosity. They work by mimicking hormones within the intestine and the mind to manage urge for food and emotions of fullness. However they don’t work for everyone and might produce unwanted effects that embody nausea and abdomen ache.
Supplies of the drugs have improved this yr, and a few insurance coverage protection is rising. That helps enhance entry to medication that may price round $500 a month with out protection. That may put them out of reach for a lot of sufferers.
The therapies are injectable medication, however Novo and Lilly are additionally growing easier-to-take capsule variations.
U.S. gross sales of Lilly’s weight-loss therapy Zepbound practically tripled, to $3.57 billion, within the third quarter. In the meantime, income from the diabetes drug Mounjaro, which has been in the marketplace longer, has doubled, to $6.52 billion, due to development outdoors the U.S.
Mixed, the medication have introduced in practically $25 billion in gross sales thus far this yr for Indianapolis-based Lilly. That surpasses the whole firm’s income whole from 2020.
The medication helped Eli Lilly and Co. file a $5.58 billion revenue within the third quarter and ship a greater efficiency than Wall Avenue anticipated.
Novo Nordisk mentioned it is going to pay $56.50 in money for every Metsera share and will pay an additional $21.25 if the corporate meets some drug growth milestones. The drugmaker already has the weight problems and diabetes therapies Wegovy and Ozempic in the marketplace.
That mixed whole of $77.75 greater than doubles the closing value of Metsera shares on September 19, the final buying and selling day earlier than Pfizer made its provide.
Metsera mentioned Thursday that its board has decided that the brand new, unsolicited provide from Novo was superior, and Pfizer has 4 enterprise days to barter changes to its provide.
Pfizer referred to as Novo’s provide “reckless and unprecedented” and an try by a drugmaker with a “dominant market place to suppress competitors in violation of legislation by taking on an rising American challenger.”
Pfizer Inc. is thought for the COVID-19 vaccine Comirnaty and the therapy Paxlovid, amongst different medication. However the New York drugmaker determined to take one other stab at weight problems therapies months after ending development of its personal drug.
—By Tom Murphy, AP well being author
AP Well being Author JoNel Aleccia contributed to this report.
